This work contains a Foreword by Merrill Goozner, Author and Director, Integrity in Science, Center for Science and the Public Interest, Washington DC. This book exposes why healthcare costs have been rapidly increasing and includes a close examination of over-priced drugs. It contains a detailed explanation of how the drug industry takes billions of dollars from society each year and proposes radical new ideas to reign in excessive spending on medicine. Based on the latest research, its unique approach takes into account the pharmaceutical industry, healthcare policy and society to offer a wide ranging account. It is invaluable for all healthcare professionals, especially managers and doctors and nurses with budgetary responsibilities. It will also be useful for researchers, policy makers and shapers, pharmaceutical company executives and general readers with an interest in medical expenditure. "While most discussions about the fiscal problems caused by aging societies have focused on pensions and income security, the more serious landmine in the road ahead is health-care finance, which will be in full-blown crisis sometime early in the next decade. That's why this book is timely. Until we learn to talk openly and honestly about what constitutes good health, good health care, and the best and most cost-effective way of achieving both, we'll never have an affordable health-care system." - Merrill Goozner, in the Foreword.
The cost of medical care: how much is too much? The nuts and bolts of medical research. Conflict of interest: a major problem in medical research. Drug regulation: two paradigms in conflict. The marketing of drugs: how drug companies manipulate the prescribing habits of doctors. Pricing pharmaceutical drugs in the USA. Potential savings from therapeutic substitution of ten of Canada's most dispensed prescription drugs. Statins: is the net being thrown too wide? Modern western medicine: lots of bucks: where's the bang? Genetics, genomic medicine, and achieving better population health: a flawed strategy. Issues in screening for cancer. The Canadian National Breast Screening Study: science meets controversy. Screening for breast cancer: benefits versus costs. Screening for cervical cancer by Pap tests. Paying for what works: the Reference Drug Program as a model for rational policy making. Disease prevention: the neglected alternative. Promoting the health of the medical profession: environmentalism and commercialism in medical education. A proposed new grand strategy: an integrated health system for the 21st century.